Patient Square Capital LP bought a new stake in Geron Co. (NASDAQ:GERN - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,321,268 shares of the biopharmaceutical company's stock, valued at approximately $4,677,000. Geron comprises approximately 1.7% of Patient Square Capital LP's investment portfolio, making the stock its 9th largest holding. Patient Square Capital LP owned about 0.22% of Geron at the end of the most recent reporting period.
Other institutional investors and hedge funds have also made changes to their positions in the company. Barclays PLC grew its stake in Geron by 114.9% during the 3rd quarter. Barclays PLC now owns 1,299,912 shares of the biopharmaceutical company's stock valued at $5,902,000 after purchasing an additional 694,931 shares in the last quarter. Moody National Bank Trust Division increased its stake in shares of Geron by 76.6% in the fourth quarter. Moody National Bank Trust Division now owns 267,629 shares of the biopharmaceutical company's stock worth $947,000 after purchasing an additional 116,074 shares during the period. Rovin Capital UT ADV raised its holdings in Geron by 26.9% in the 4th quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company's stock valued at $61,000 after acquiring an additional 3,660 shares in the last quarter. Hennion & Walsh Asset Management Inc. grew its position in Geron by 18.1% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 403,703 shares of the biopharmaceutical company's stock worth $1,429,000 after acquiring an additional 61,819 shares during the last quarter. Finally, Monterey Private Wealth Inc. bought a new position in Geron in the 4th quarter valued at $63,000. 73.71% of the stock is currently owned by hedge funds and other institutional investors.
Geron Stock Up 7.4%
Shares of Geron stock traded up $0.09 during trading on Monday, hitting $1.36. 4,932,870 shares of the stock were exchanged, compared to its average volume of 11,615,405. Geron Co. has a 12-month low of $1.17 and a 12-month high of $5.34. The stock has a market cap of $868.76 million, a price-to-earnings ratio of -4.23 and a beta of 0.76. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74. The firm's 50-day moving average price is $1.44 and its 200 day moving average price is $2.61.
Geron (NASDAQ:GERN - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.01. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The company had revenue of $39.60 million for the quarter, compared to analyst estimates of $49.88 million. During the same period in the prior year, the business posted ($0.07) earnings per share. The firm's revenue for the quarter was up 12927.3% compared to the same quarter last year. As a group, analysts forecast that Geron Co. will post -0.25 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several equities analysts have recently weighed in on the company. B. Riley cut Geron from a "buy" rating to a "neutral" rating and decreased their price objective for the company from $3.50 to $2.00 in a report on Thursday, February 27th. HC Wainwright reaffirmed a "neutral" rating on shares of Geron in a research report on Wednesday, March 12th. Needham & Company LLC reaffirmed a "buy" rating and issued a $5.00 price objective on shares of Geron in a report on Wednesday, March 12th. Stifel Nicolaus dropped their price objective on shares of Geron from $8.00 to $4.00 and set a "buy" rating for the company in a report on Thursday, February 27th. Finally, Barclays reissued an "overweight" rating and issued a $4.00 price target (down from $9.00) on shares of Geron in a research note on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $5.06.
View Our Latest Stock Report on GERN
About Geron
(
Free Report)
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
See Also
Before you consider Geron, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Geron wasn't on the list.
While Geron currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
